EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 100-150 MG TAB

For 30 tablets

Pharmacies pay

$305.83 filed

30 × $10.19448 per EA

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-04-22 · as of 2026-10-14 · retrieved 2026-10-17

Medicare

We don’t know yet

No Medicare reference price. Part D: OpenBill did not match this NDC to a usable Medicare Part D spending row. Either Part D has none for it, or the rows that share its name could not safely be tied to it (for example, they mix units, routes or release forms, or the drug is sold over the counter, which Part D does not cover). Part B: This NDC is not in the current quarter’s Medicare Part B NDC-HCPCS crosswalk, so it has no Part B payment limit.

The spread

We don’t know yet

There is no Medicare figure to compare with, so there is no spread.

Cost-plus estimate

$356.70 estimated

$305.83 + $45.87 (15%) + $5.00 fee per fill = $356.70

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-04-22 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 100-150 MG TAB is how the CMS NADAC file names this product. The FDA NDC Directory lists it as emtricitabine and tenofovir disoproxil fumarate.

FDA gives its dosage form as tablet, film coated and its route as oral.

Its labelers, the companies named on the label, are Aurobindo Pharma Limited, Amneal Pharmaceuticals NY LLC and Zydus Pharmaceuticals USA Inc.

FDA lists it under 2 Established Pharmacologic Classes: Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor and Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor.

The NADAC file of 2026-10-14 prices it under 3 NDCs (National Drug Codes).

NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $305.83 for 30 tablets (30 × $10.19448 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-04-22. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation code for it: 4, carried forward from the previous file.

The NADAC of all 3 NDCs was carried forward from an earlier file (NADAC explanation code 2 or 4), not newly surveyed: those prices took effect on 2026-04-22. The file is new; the price is not.

What NADAC measures · Why 30 tablets · NADAC explanation codes · Carried-forward prices

All 3 NDCs

59651-0165-30 · Aurobindo Pharma Limited · $10.19448 per EA · eff. 2026-04-22 filed carried forward
69238-2092-03 · Amneal Pharmaceuticals NY LLC · $10.19448 per EA · eff. 2026-04-22 filed carried forward
70710-1364-03 · Zydus Pharmaceuticals USA Inc. · $10.19448 per EA · eff. 2026-04-22 filed carried forward

Other strengths, forms and brands

2 other products in the NADAC file share the FDA nonproprietary name emtricitabine and tenofovir disoproxil fumarate with EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 100-150 MG TAB.

Product	Pharmacies pay per unit	Medicare per unit
EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 100-150 MG TAB this page generic · tablet, film coated	$10.19448 per EA filed eff. 2026-04-22	We don’t know yet
EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB generic · tablet, film coated	$0.52902 per EA filed eff. 2026-09-23	We don’t know yet
TRUVADA 200 MG-300 MG TABLET brand · tablet, film coated	$59.70975 per EA filed eff. 2026-09-23	$57.85288 per EA filed Part D 2024 average

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-04-22, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

Compared with its class

The middle of its 3 NDCs’ NADAC prices is $10.19448 per EA filed.

Of the 28 other products in FDA’s Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class priced per EA, 18 have a higher middle NADAC price and 10 a lower one. The one in the middle is VEMLIDY 25 MG TABLET, at $51.98384 per EA filed (eff. 2026-09-23).

Of the 28 other products in FDA’s Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor class priced per EA, 18 have a higher middle NADAC price and 10 a lower one. The one in the middle is VEMLIDY 25 MG TABLET, at $51.98384 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-04-22, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

We don’t know yet; the card above says why.

Which Medicare figure OpenBill compares · How Part D is matched · How Part B is matched

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

What is your cash price for 30 tablets? Is it lower than what I would pay through my insurance?
These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.